Akari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research note issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Trading Down 7.5 %

Shares of NASDAQ AKTX opened at $1.36 on Thursday. The stock has a fifty day moving average price of $1.69 and a 200 day moving average price of $2.53. Akari Therapeutics has a 12-month low of $1.08 and a 12-month high of $5.50.

Hedge Funds Weigh In On Akari Therapeutics

An institutional investor recently raised its position in Akari Therapeutics stock. Omnia Family Wealth LLC lifted its position in shares of Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 87,628 shares of the biopharmaceutical company’s stock after purchasing an additional 28,511 shares during the period. Omnia Family Wealth LLC owned about 1.55% of Akari Therapeutics worth $273,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 5.06% of the company’s stock.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.